Ken Griffin Purple Biotech Ltd. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.41 - $0.86 $410 - $860	-1,000 Reduced 15.15%	5,600 $2,000
Q1 2024 May 15, 2024	BUY	$0.58 - $0.92 $174 - $276	300 Added 4.76%	6,600 $4,000
Q4 2023 Feb 14, 2024	BUY	$0.78 - $1.67 $1,248 - $2,672	1,600 Added 34.04%	6,300 $4,000
Q3 2023 Nov 14, 2023	SELL	$1.02 - $1.49 $4,386 - $6,407	-4,300 Reduced 47.78%	4,700 $5,000
Q2 2023 Aug 14, 2023	SELL	$1.38 - $2.05 $37,950 - $56,374	-27,500 Reduced 75.34%	9,000 $12,000
Q1 2023 May 15, 2023	SELL	$1.36 - $2.3 $39,848 - $67,390	-29,300 Reduced 44.53%	36,500 $65,000
Q4 2022 Feb 14, 2023	SELL	$1.38 - $2.22 $23,184 - $37,296	-16,800 Reduced 20.34%	65,800 $90,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $2.69 $130,720 - $185,072	68,800 Added 498.55%	82,600 $168,000

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $67M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.